The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
Author:
Publisher
Elsevier BV
Subject
Urology
Reference99 articles.
1. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017
2. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial;Powles;Lancet,2018
3. Cancer immunology. The “cancer immunogram”;Blank;Science,2016
4. An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer;Karasaki;J Thorac Oncol,2017
5. The makings of a tumor rejection antigen;Gilboa;Immunity,1999
Cited by 90 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer;Scientific Reports;2023-12-09
2. Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis;Life Sciences;2023-12
3. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma;Cancer Biomarkers;2023-11-20
4. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer;Frontiers in Immunology;2023-10-27
5. Immunotherapy in urothelial cancer: current status and future directions;Expert Review of Anticancer Therapy;2023-10-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3